GSK plc (GSK)

NYSE: GSK · Real-Time Price · USD
36.29
-0.37 (-1.01%)
Nov 8, 2024, 4:00 PM EST - Market closed
-1.01%
Market Cap 72.83B
Revenue (ttm) 41.97B
Net Income (ttm) 3.37B
Shares Out 4.08B
EPS (ttm) 0.81
PE Ratio 21.64
Forward PE 8.29
Dividend $1.56 (4.29%)
Ex-Dividend Date Nov 15, 2024
Volume 8,865,807
Open 36.12
Previous Close 36.66
Day's Range 36.10 - 36.42
52-Week Range 33.89 - 45.93
Beta 0.33
Analysts Hold
Price Target 48.00 (+32.27%)
Earnings Date Oct 30, 2024

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]

Sector Healthcare
Founded 1715
Employees 70,212
Stock Exchange NYSE
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2023, GSK's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for GSK stock is "Hold." The 12-month stock price forecast is $48.0, which is an increase of 32.27% from the latest price.

Price Target
$48.0
(32.27% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Canada approves GSK's RSV vaccine for adults aged 50 to 59

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age ...

5 days ago - Reuters

GSK plc (GSK) Q3 2024 Earnings Call Transcript

GSK plc (NYSE:GSK) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcar...

11 days ago - Seeking Alpha

GSK: Earnings Confirm It's On Track To Meet Guidance

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core EPS gr...

11 days ago - Seeking Alpha

GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024

Wednesday, GSK Plc GSK reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of $10.78 bill...

11 days ago - Benzinga

GSK Stock Drops as UK Firm Posts Underwhelming Results

GSK's (GSK) shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales.

11 days ago - Investopedia

GSK cuts vaccine sales target on reduced demand

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.

11 days ago - Market Watch

GSK lowers 2024 vaccine sales forecast

GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.

11 days ago - Reuters

Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY

-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for...

12 days ago - PRNewsWire

GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company's diversified portfolio in...

15 days ago - Seeking Alpha

New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

PHILADELPHIA--(BUSINESS WIRE)-- #Adult--New data for AREXVY, GSK's RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.

17 days ago - Business Wire

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Other symbols: OGNPINC
20 days ago - Benzinga

GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines

GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.

Other symbols: MRNA
26 days ago - Reuters

GSK: The Worst Is Finally Over (Rating Upgrade)

GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 2024...

4 weeks ago - Seeking Alpha

GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement

GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caus...

4 weeks ago - WSJ

GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits

GSK (GSK) shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes ...

4 weeks ago - Investopedia

GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US related ...

4 weeks ago - Invezz

GSK settles vast majority of Zantac claims for $2.2 billion

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn remedy causes cancer

4 weeks ago - Market Watch

GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits

Shares of GSK are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits that claimed its discontinued heartburn...

4 weeks ago - Reuters

GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac

British drugmaker agrees payment to resolve 80,000 cases alleging cancers were linked to drug known generically as ranitidine

4 weeks ago - The Guardian

GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.

4 weeks ago - WSJ

GlaxoSmithKline Reaches $2.2 Billion Settlement in Zantac Lawsuits

GlaxoSmithKline (GSK, Financial) has agreed to a substantial settlement in connection with lawsuits related to its Zantac product in U.S. state courts. The company announced that it reached settlement...

4 weeks ago - GuruFocus

GSK reaches up to $2.2 billion settlement in Zantac US state court cases

GSK said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court Zantac product liability cases pending against the drugmaker, for up to $2.2 billion.

4 weeks ago - Reuters

GSK Reports Sustained Efficacy of RSV Vaccine Amidst Competition from Pfizer and Moderna

GSK (GSK, Financial) announced that its respiratory syncytial virus (RSV) vaccine has shown protective benefits for three quarters following vaccination. The cumulative efficacy of the vaccine, adjust...

4 weeks ago - GuruFocus

RSV Vaccine Demand Drops Sharply in the US, Impacting GSK's Sales

Recent data indicates a significant drop in the sales of the respiratory syncytial virus (RSV) vaccine in the United States. Major vaccine manufacturers, including GlaxoSmithKline (GSK, Financial), Mo...

4 weeks ago - GuruFocus

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

PHILADELPHIA--(BUSINESS WIRE)-- #AdultVaccination--GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons.

4 weeks ago - Business Wire